Related Experiment Video

Updated: Jul 7, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Effect of hepatitis C infection on anemia in hemodialysis patients

Anand Khurana1, Allan E Nickel, Mohanram Narayanan

  • 1Department of Nephrology, Scott & White Clinic, Texas A&M University, Temple, Texas, U.S.A. anandkhurana@yahoo.com

Hemodialysis International. International Symposium on Home Hemodialysis
|February 15, 2008
PubMed

Insights

Hepatitis C (HCV) infection in dialysis patients is linked to lower erythropoietin (EPO) needs. While iron requirements weren't significantly different, this study suggests potential impacts on anemia management in hemodialysis patients.

Area of Science:

  • Nephrology
  • Hepatology
  • Infectious Diseases

Background:

  • Hepatitis C (HCV) is prevalent in dialysis patients, but its long-term effects on anemia are not well understood.
  • Anemia management in hemodialysis patients often involves erythropoietin (EPO) and iron supplementation.
  • Understanding HCV's impact on anemia is crucial for optimizing treatment in this population.

Purpose of the Study:

  • To evaluate the effect of Hepatitis C (HCV) infection on anemia and its management in hemodialysis patients.
  • To compare erythropoietin (EPO) and intravenous (IV) iron requirements between HCV-positive and HCV-negative hemodialysis patients.
  • To investigate the long-term consequences of HCV on anemia in a chronic kidney disease population.

Main Methods:

  • Retrospective case-control study from January 1999 to February 2007.
  • Compared 22 HCV-positive patients with 44 age-, race-, and gender-matched HCV-negative hemodialysis controls.
  • Assessed anemia, iron stores, dialysis adequacy, alanine aminotransferase, EPO, and IV iron requirements over a 12-month period.

Main Results:

  • HCV-positive patients required significantly lower mean doses of erythropoietin (EPO) (17,307 U/month) compared to controls (49,134 U/month) (p < 0.01).
  • Mean intravenous (IV) iron requirements showed a trend towards being lower in HCV-positive patients (120 mg/month) versus controls (163 mg/month), though not statistically significant (p=0.07).
  • Alanine aminotransferase levels and dialysis adequacy were assessed but not detailed in the abstract's results summary.

Conclusions:

  • Hepatitis C (HCV) infected hemodialysis patients demonstrate a reduced need for exogenous erythropoietin (EPO) replacement therapy.
  • Intravenous (IV) iron requirements did not differ significantly, but a lower trend in HCV patients warrants further investigation.
  • Larger clinical trials are needed to confirm these findings and explore the underlying mechanisms in HCV-positive dialysis patients.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...